Literature DB >> 15843517

TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells.

Mojgan Ahmadzadeh1, Steven A Rosenberg.   

Abstract

TGF-beta1 is a potent immunoregulatory cytokine. However, its impact on the generation and effector function of Ag-specific human effector memory CD8 T cells had not been evaluated. Using Ag-specific CD8 T cells derived from melanoma patients immunized with the gp100 melanoma Ag, we demonstrate that the addition of TGF-beta1 to the initial Ag activation cultures attenuated the gain of effector function by Ag-specific memory CD8 T cells while the phenotypic changes associated with activation and differentiation into effector memory were comparable to control cultures. These activated memory CD8 T cells consistently expressed lower mRNA levels for T-bet, suggesting a mechanism for TGF-beta1-mediated suppression of gain of effector function in memory T cells. Moreover, TGF-beta1 induced a modest expression of CCR7 on Ag-activated memory CD8 T cells. TGF-beta1 also suppressed cytokine secretion by Ag-specific effector memory CD8 T cells, as well as melanoma-reactive tumor-infiltrating lymphocytes and CD8 T cell clones. These results demonstrate that TGF-beta1 suppresses not only the acquisition but also expression of effector function on human memory CD8 T cells and tumor-infiltrating lymphocytes reactive against melanoma, suggesting that TGF-beta1-mediated suppression can hinder the therapeutic benefits of vaccination, as well as immunotherapy in cancer patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15843517      PMCID: PMC2562293          DOI: 10.4049/jimmunol.174.9.5215

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  44 in total

1.  CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs.

Authors:  R Förster; A Schubel; D Breitfeld; E Kremmer; I Renner-Müller; E Wolf; M Lipp
Journal:  Cell       Date:  1999-10-01       Impact factor: 41.582

2.  A novel transcription factor, T-bet, directs Th1 lineage commitment.

Authors:  S J Szabo; S T Kim; G L Costa; X Zhang; C G Fathman; L H Glimcher
Journal:  Cell       Date:  2000-03-17       Impact factor: 41.582

Review 3.  Chemokines in tissue-specific and microenvironment-specific lymphocyte homing.

Authors:  J J Campbell; E C Butcher
Journal:  Curr Opin Immunol       Date:  2000-06       Impact factor: 7.486

4.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.

Authors:  F Sallusto; D Lenig; R Förster; M Lipp; A Lanzavecchia
Journal:  Nature       Date:  1999-10-14       Impact factor: 49.962

5.  Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression.

Authors:  L Gorelik; P E Fields; R A Flavell
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

6.  Status of activation of circulating vaccine-elicited CD8+ T cells.

Authors:  M B Nielsen; V Monsurro; S A Migueles; E Wang; A Perez-Diez; K H Lee; U Kammula; S A Rosenberg; F M Marincola
Journal:  J Immunol       Date:  2000-08-15       Impact factor: 5.422

Review 7.  Progress in human tumour immunology and immunotherapy.

Authors:  S A Rosenberg
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

8.  Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease.

Authors:  L Gorelik; R A Flavell
Journal:  Immunity       Date:  2000-02       Impact factor: 31.745

9.  Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma.

Authors:  M E Dudley; J Wunderlich; M I Nishimura; D Yu; J C Yang; S L Topalian; D J Schwartzentruber; P Hwu; F M Marincola; R Sherry; S F Leitman; S A Rosenberg
Journal:  J Immunother       Date:  2001 Jul-Aug       Impact factor: 4.456

10.  Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor beta II receptor.

Authors:  P J Lucas; S J Kim; S J Melby; R E Gress
Journal:  J Exp Med       Date:  2000-04-03       Impact factor: 14.307

View more
  73 in total

1.  Detection and characterization of a novel subset of CD8⁺CD57⁺ T cells in metastatic melanoma with an incompletely differentiated phenotype.

Authors:  Richard C Wu; Shujuan Liu; Jessica A Chacon; Sheng Wu; Yufeng Li; Pariya Sukhumalchandra; James L Murray; Jeffrey J Molldrem; Patrick Hwu; Hanspeter Pircher; Gregory Lizée; Laszlo G Radvanyi
Journal:  Clin Cancer Res       Date:  2012-02-03       Impact factor: 12.531

Review 2.  Programming CD8+ T cells for effective immunotherapy.

Authors:  Christian S Hinrichs; Luca Gattinoni; Nicholas P Restifo
Journal:  Curr Opin Immunol       Date:  2006-04-17       Impact factor: 7.486

Review 3.  Negative regulators in homeostasis of naïve peripheral T cells.

Authors:  Jaime F Modiano; Lisa D S Johnson; Donald Bellgrau
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 4.  Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.

Authors:  Adam J Bograd; Kei Suzuki; Eva Vertes; Christos Colovos; Eduardo A Morales; Michel Sadelain; Prasad S Adusumilli
Journal:  Cancer Immunol Immunother       Date:  2011-09-13       Impact factor: 6.968

Review 5.  Secretion of immunoregulatory cytokines by mesenchymal stem cells.

Authors:  Dobroslav Kyurkchiev; Ivan Bochev; Ekaterina Ivanova-Todorova; Milena Mourdjeva; Tsvetelina Oreshkova; Kalina Belemezova; Stanimir Kyurkchiev
Journal:  World J Stem Cells       Date:  2014-11-26       Impact factor: 5.326

6.  Enhancing Adoptive Cell Therapy of Cancer through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors.

Authors:  Yiran Zheng; Li Tang; Llian Mabardi; Sudha Kumari; Darrell J Irvine
Journal:  ACS Nano       Date:  2017-03-01       Impact factor: 15.881

7.  Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy.

Authors:  Samuel Kim; George Buchlis; Zvi G Fridlender; Jing Sun; Veena Kapoor; Guanjun Cheng; Andrew Haas; Hung Kam Cheung; Xiamei Zhang; Michael Corbley; Larry R Kaiser; Leona Ling; Steven M Albelda
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

Review 8.  Transforming growth factor beta (TGF-beta) and inflammation in cancer.

Authors:  Brian Bierie; Harold L Moses
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-16       Impact factor: 7.638

9.  Opposing effects of TGF-beta and IL-15 cytokines control the number of short-lived effector CD8+ T cells.

Authors:  Shomyseh Sanjabi; Munir M Mosaheb; Richard A Flavell
Journal:  Immunity       Date:  2009-07-17       Impact factor: 31.745

10.  Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells.

Authors:  Shun Takaku; Masaki Terabe; Elena Ambrosino; Judy Peng; Scott Lonning; John M McPherson; Jay A Berzofsky
Journal:  Int J Cancer       Date:  2010-04-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.